Which has better valuation & earnings, GUTS or QTTB?

Q32 Bio has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fractyl Health $90K 1,215.60 -$140.95M -$0.88 N/A Q32 Bio $53.74M 7.09 $29.82M $3.00 4.27

Is GUTS or QTTB more profitable?

Q32 Bio's return on equity of 50.17% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Q32 Bio N/A 50.17% 29.49%

Does the media favor GUTS or QTTB?

In the previous week, Fractyl Health had 20 more articles in the media than Q32 Bio. MarketBeat recorded 23 mentions for Fractyl Health and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 0.43 beat Fractyl Health's score of 0.08 indicating that Q32 Bio is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 2 Very Positive mention(s) 1 Positive mention(s) 18 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Q32 Bio 2 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GUTS or PRLD more profitable?

Prelude Therapeutics' return on equity of -75.35% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Prelude Therapeutics N/A -75.35% -44.39%

Does the media refer more to GUTS or PRLD?

In the previous week, Fractyl Health had 21 more articles in the media than Prelude Therapeutics. MarketBeat recorded 23 mentions for Fractyl Health and 2 mentions for Prelude Therapeutics. Fractyl Health's average media sentiment score of 0.08 beat Prelude Therapeutics' score of -0.17 indicating that Fractyl Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 2 Very Positive mention(s) 1 Positive mention(s) 18 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Prelude Therapeutics 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 1 Negative mention(s) 0 Very Negative mention(s) Neutral

Which has preferable valuation and earnings, GUTS or OCGN?

Ocugen has higher revenue and earnings than Fractyl Health. Ocugen is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks. Company Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio Fractyl Health $90K 1,215.60 -$140.95M -$0.88 N/A Ocugen $4.41M 103.81 -$67.85M -$0.26 N/A

Is GUTS or OCGN more profitable?

Fractyl Health's return on equity of -1,362.10% beat Ocugen's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Ocugen N/A -127,987.80% -115.95%

Does the media favor GUTS or OCGN?

In the previous week, Fractyl Health had 16 more articles in the media than Ocugen. MarketBeat recorded 23 mentions for Fractyl Health and 7 mentions for Ocugen. Ocugen's average media sentiment score of 0.66 beat Fractyl Health's score of 0.08 indicating that Ocugen is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 2 Very Positive mention(s) 1 Positive mention(s) 18 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Ocugen 3 Very Positive mention(s) 1 Positive mention(s) 3 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Is GUTS or RZLT more profitable?

Rezolute's return on equity of -58.82% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Rezolute N/A -58.82% -54.48%

Does the media favor GUTS or RZLT?

In the previous week, Fractyl Health had 22 more articles in the media than Rezolute. MarketBeat recorded 23 mentions for Fractyl Health and 1 mentions for Rezolute. Fractyl Health's average media sentiment score of 0.08 beat Rezolute's score of 0.00 indicating that Fractyl Health is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 2 Very Positive mention(s) 1 Positive mention(s) 18 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Rezolute 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral

Is GUTS or EPRX more profitable?

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Fractyl Health's return on equity. Company Net Margins Return on Equity Return on Assets Fractyl Health N/A -1,362.10% -84.89% Eupraxia Pharmaceuticals N/A -63.97% -43.32%

Does the media refer more to GUTS or EPRX?

In the previous week, Fractyl Health had 18 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 23 mentions for Fractyl Health and 5 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.12 beat Fractyl Health's score of 0.08 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Fractyl Health 2 Very Positive mention(s) 1 Positive mention(s) 18 Neutral mention(s) 2 Negative mention(s) 0 Very Negative mention(s) Neutral Eupraxia Pharmaceuticals 3 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive

Fractyl Health (GUTS) Competitors

$0.69 -0.02 (-2.75%)

As of 09/3/2026 04:00 PM Eastern

Compare

GUTS vs. QTTB, PRLD, OCGN, RZLT, and EPRX

Should you buy Fractyl Health stock or one of its competitors? Fractyl Health's main competitors and comparable companies include Q32 Bio (QTTB), Prelude Therapeutics (PRLD), Ocugen (OCGN), Rezolute (RZLT), and Eupraxia Pharmaceuticals (EPRX). Companies are selected based on similarities in market, industry, and size. These companies are all part of the "biotechnology" industry.

How does Fractyl Health compare to Q32 Bio?

Fractyl Health (NASDAQ:GUTS) and Q32 Bio (NASDAQ:QTTB) are both small-cap healthcare companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, earnings, dividends, institutional ownership, valuation, risk, media sentiment and profitability.

31.3% of Q32 Bio shares are owned by institutional investors. 8.4% of Fractyl Health shares are owned by company insiders. Comparatively, 34.5% of Q32 Bio shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.

Q32 Bio's return on equity of 50.17% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Q32 Bio	N/A	50.17%	29.49%

Fractyl Health has a beta of 2.34, indicating that its share price is 134% more volatile than the broader market. Comparatively, Q32 Bio has a beta of 0.21, indicating that its share price is 79% less volatile than the broader market.

Q32 Bio has higher revenue and earnings than Fractyl Health. Fractyl Health is trading at a lower price-to-earnings ratio than Q32 Bio, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,215.60	-$140.95M	-$0.88	N/A
Q32 Bio	$53.74M	7.09	$29.82M	$3.00	4.27

In the previous week, Fractyl Health had 20 more articles in the media than Q32 Bio. MarketBeat recorded 23 mentions for Fractyl Health and 3 mentions for Q32 Bio. Q32 Bio's average media sentiment score of 0.43 beat Fractyl Health's score of 0.08 indicating that Q32 Bio is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	2 Very Positive mention(s)	1 Positive mention(s)	18 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Q32 Bio	2 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fractyl Health presently has a consensus price target of $5.50, suggesting a potential upside of 700.23%. Q32 Bio has a consensus price target of $31.00, suggesting a potential upside of 142.19%. Given Fractyl Health's higher possible upside, equities analysts clearly believe Fractyl Health is more favorable than Q32 Bio.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Q32 Bio	0 Sell rating(s)	2 Hold rating(s)	5 Buy rating(s)	0 Strong Buy rating(s)	2.71

Summary

Q32 Bio beats Fractyl Health on 11 of the 15 factors compared between the two stocks.

How does Fractyl Health compare to Prelude Therapeutics?

Fractyl Health (NASDAQ:GUTS) and Prelude Therapeutics (NASDAQ:PRLD) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their analyst recommendations, earnings, institutional ownership, media sentiment, valuation, dividends, risk and profitability.

Prelude Therapeutics' return on equity of -75.35% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Prelude Therapeutics	N/A	-75.35%	-44.39%

Fractyl Health currently has a consensus target price of $5.50, suggesting a potential upside of 700.23%. Prelude Therapeutics has a consensus target price of $7.67, suggesting a potential upside of 46.03%. Given Fractyl Health's higher possible upside, equities research analysts plainly believe Fractyl Health is more favorable than Prelude Therapeutics.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Prelude Therapeutics	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40

Prelude Therapeutics has higher revenue and earnings than Fractyl Health. Prelude Therapeutics is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,215.60	-$140.95M	-$0.88	N/A
Prelude Therapeutics	$12.14M	34.51	-$99.50M	-$0.73	N/A

In the previous week, Fractyl Health had 21 more articles in the media than Prelude Therapeutics. MarketBeat recorded 23 mentions for Fractyl Health and 2 mentions for Prelude Therapeutics. Fractyl Health's average media sentiment score of 0.08 beat Prelude Therapeutics' score of -0.17 indicating that Fractyl Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	2 Very Positive mention(s)	1 Positive mention(s)	18 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Prelude Therapeutics	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral

Fractyl Health has a beta of 2.34, indicating that its stock price is 134% more volatile than the broader market. Comparatively, Prelude Therapeutics has a beta of 0.97, indicating that its stock price is 3% less volatile than the broader market.

79.7% of Prelude Therapeutics shares are owned by institutional investors. 8.4% of Fractyl Health shares are owned by insiders. Comparatively, 49.2% of Prelude Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company is poised for long-term growth.

Summary

Prelude Therapeutics beats Fractyl Health on 7 of the 13 factors compared between the two stocks.

How does Fractyl Health compare to Ocugen?

Fractyl Health (NASDAQ:GUTS) and Ocugen (NASDAQ:OCGN) are both small-cap healthcare companies, but which is the superior business? We will contrast the two businesses based on the strength of their earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.

In the previous week, Fractyl Health had 16 more articles in the media than Ocugen. MarketBeat recorded 23 mentions for Fractyl Health and 7 mentions for Ocugen. Ocugen's average media sentiment score of 0.66 beat Fractyl Health's score of 0.08 indicating that Ocugen is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	2 Very Positive mention(s)	1 Positive mention(s)	18 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Ocugen	3 Very Positive mention(s)	1 Positive mention(s)	3 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Ocugen has higher revenue and earnings than Fractyl Health. Ocugen is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,215.60	-$140.95M	-$0.88	N/A
Ocugen	$4.41M	103.81	-$67.85M	-$0.26	N/A

Fractyl Health has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market. Comparatively, Ocugen has a beta of 2.2, meaning that its stock price is 120% more volatile than the broader market.

10.3% of Ocugen shares are owned by institutional investors. 8.4% of Fractyl Health shares are owned by insiders. Comparatively, 4.0% of Ocugen shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.

Fractyl Health's return on equity of -1,362.10% beat Ocugen's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Ocugen	N/A	-127,987.80%	-115.95%

Fractyl Health presently has a consensus price target of $5.50, suggesting a potential upside of 700.23%. Ocugen has a consensus price target of $9.50, suggesting a potential upside of 603.70%. Given Fractyl Health's higher probable upside, equities research analysts plainly believe Fractyl Health is more favorable than Ocugen.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Ocugen	1 Sell rating(s)	0 Hold rating(s)	4 Buy rating(s)	0 Strong Buy rating(s)	2.60

Summary

Fractyl Health beats Ocugen on 8 of the 15 factors compared between the two stocks.

How does Fractyl Health compare to Rezolute?

Fractyl Health (NASDAQ:GUTS) and Rezolute (NASDAQ:RZLT) are both small-cap healthcare companies, but which is the superior investment? We will contrast the two companies based on the strength of their earnings, media sentiment, dividends, profitability, institutional ownership, analyst recommendations, risk and valuation.

Rezolute has lower revenue, but higher earnings than Fractyl Health. Rezolute is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,215.60	-$140.95M	-$0.88	N/A
Rezolute	N/A	N/A	-$74.41M	-$0.82	N/A

Fractyl Health has a beta of 2.34, meaning that its stock price is 134% more volatile than the broader market. Comparatively, Rezolute has a beta of 0.6, meaning that its stock price is 40% less volatile than the broader market.

Fractyl Health currently has a consensus target price of $5.50, suggesting a potential upside of 700.23%. Rezolute has a consensus target price of $9.38, suggesting a potential upside of 106.50%. Given Fractyl Health's higher possible upside, research analysts clearly believe Fractyl Health is more favorable than Rezolute.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Rezolute	1 Sell rating(s)	3 Hold rating(s)	8 Buy rating(s)	0 Strong Buy rating(s)	2.58

Rezolute's return on equity of -58.82% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Rezolute	N/A	-58.82%	-54.48%

83.0% of Rezolute shares are held by institutional investors. 8.4% of Fractyl Health shares are held by company insiders. Comparatively, 14.8% of Rezolute shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a company will outperform the market over the long term.

In the previous week, Fractyl Health had 22 more articles in the media than Rezolute. MarketBeat recorded 23 mentions for Fractyl Health and 1 mentions for Rezolute. Fractyl Health's average media sentiment score of 0.08 beat Rezolute's score of 0.00 indicating that Fractyl Health is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	2 Very Positive mention(s)	1 Positive mention(s)	18 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Rezolute	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Rezolute beats Fractyl Health on 8 of the 14 factors compared between the two stocks.

How does Fractyl Health compare to Eupraxia Pharmaceuticals?

Fractyl Health (NASDAQ:GUTS) and Eupraxia Pharmaceuticals (NASDAQ:EPRX) are both small-cap healthcare companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, earnings, analyst recommendations, profitability and valuation.

Fractyl Health has a beta of 2.34, indicating that its share price is 134% more volatile than the broader market. Comparatively, Eupraxia Pharmaceuticals has a beta of 1.07, indicating that its share price is 7% more volatile than the broader market.

In the previous week, Fractyl Health had 18 more articles in the media than Eupraxia Pharmaceuticals. MarketBeat recorded 23 mentions for Fractyl Health and 5 mentions for Eupraxia Pharmaceuticals. Eupraxia Pharmaceuticals' average media sentiment score of 1.12 beat Fractyl Health's score of 0.08 indicating that Eupraxia Pharmaceuticals is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Fractyl Health	2 Very Positive mention(s)	1 Positive mention(s)	18 Neutral mention(s)	2 Negative mention(s)	0 Very Negative mention(s)	Neutral
Eupraxia Pharmaceuticals	3 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Fractyl Health currently has a consensus price target of $5.50, indicating a potential upside of 700.23%. Eupraxia Pharmaceuticals has a consensus price target of $18.00, indicating a potential upside of 140.00%. Given Fractyl Health's higher possible upside, research analysts clearly believe Fractyl Health is more favorable than Eupraxia Pharmaceuticals.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Fractyl Health	1 Sell rating(s)	1 Hold rating(s)	3 Buy rating(s)	0 Strong Buy rating(s)	2.40
Eupraxia Pharmaceuticals	1 Sell rating(s)	1 Hold rating(s)	5 Buy rating(s)	2 Strong Buy rating(s)	2.89

Eupraxia Pharmaceuticals has lower revenue, but higher earnings than Fractyl Health. Eupraxia Pharmaceuticals is trading at a lower price-to-earnings ratio than Fractyl Health, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Fractyl Health	$90K	1,215.60	-$140.95M	-$0.88	N/A
Eupraxia Pharmaceuticals	N/A	N/A	-$38.58M	-$1.02	N/A

Eupraxia Pharmaceuticals' return on equity of -63.97% beat Fractyl Health's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Fractyl Health	N/A	-1,362.10%	-84.89%
Eupraxia Pharmaceuticals	N/A	-63.97%	-43.32%

Summary

Eupraxia Pharmaceuticals beats Fractyl Health on 7 of the 13 factors compared between the two stocks.

Get Fractyl Health News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding GUTS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

GUTS vs. The Competition

Export

Metric	Fractyl Health	Biotechnology Industry	Healthcare Sector	NASDAQ Exchange
Market Cap	$112.49M	$4.03B	$7.26B	$12.73B
Dividend Yield	N/A	3.60%	2.53%	8.86%
P/E Ratio	-0.78	12.66	273.29	25.38
Price / Sales	1,215.60	1,309.08	613.45	92.55
Price / Cash	N/A	106.87	77.82	52.26
Price / Book	-68.73	16.29	12.89	6.14
Net Income	-$140.95M	-$22.72M	$3.47B	$349.01M
7 Day Performance	4.29%	0.34%	0.60%	-0.27%
1 Month Performance	0.34%	8.52%	5.73%	0.68%
1 Year Performance	-23.62%	52.66%	25.35%	14.84%

Fractyl Health Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
GUTS Fractyl Health	3.987 of 5 stars	$0.69 -2.7%	$5.50 +700.2%	-26.4%	$112.49M	$90K	N/A	102
QTTB Q32 Bio	3.2291 of 5 stars	$15.49 -4.1%	$31.00 +100.1%	+648.5%	$461.14M	$53.74M	5.16	39
PRLD Prelude Therapeutics	1.7048 of 5 stars	$5.77 -9.0%	$7.67 +32.9%	+330.3%	$460.45M	$12.14M	N/A	120	Positive News
OCGN Ocugen	1.8794 of 5 stars	$1.34 -2.2%	$9.50 +609.0%	+28.6%	$454.37M	$4.41M	N/A	80
RZLT Rezolute	2.0306 of 5 stars	$4.67 -6.2%	$9.38 +100.7%	-37.3%	$449.67M	N/A	N/A	40	Positive News

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:GUTS) was last updated on 9/4/2026 by MarketBeat.com Staff.

From Our Partners

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Fractyl Health (GUTS) Competitors

GUTS vs. QTTB, PRLD, OCGN, RZLT, and EPRX

How does Fractyl Health compare to Q32 Bio?

Summary

How does Fractyl Health compare to Prelude Therapeutics?

Summary

How does Fractyl Health compare to Ocugen?

Summary

How does Fractyl Health compare to Rezolute?

Summary

How does Fractyl Health compare to Eupraxia Pharmaceuticals?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUTS vs. The Competition

Fractyl Health Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Fractyl Health (GUTS) Competitors

GUTS vs. QTTB, PRLD, OCGN, RZLT, and EPRX

How does Fractyl Health compare to Q32 Bio?

Do insiders and institutionals have more ownership in GUTS or QTTB?

Is GUTS or QTTB more profitable?

Which has more volatility and risk, GUTS or QTTB?

Which has better valuation & earnings, GUTS or QTTB?

Does the media favor GUTS or QTTB?

Do analysts recommend GUTS or QTTB?

Summary

How does Fractyl Health compare to Prelude Therapeutics?

Is GUTS or PRLD more profitable?

Do analysts recommend GUTS or PRLD?

Which has preferable earnings and valuation, GUTS or PRLD?

Does the media refer more to GUTS or PRLD?

Which has more risk & volatility, GUTS or PRLD?

Do insiders & institutionals have more ownership in GUTS or PRLD?

Summary

How does Fractyl Health compare to Ocugen?

Does the media favor GUTS or OCGN?

Which has preferable valuation and earnings, GUTS or OCGN?

Which has more volatility and risk, GUTS or OCGN?

Do institutionals & insiders have more ownership in GUTS or OCGN?

Is GUTS or OCGN more profitable?

Do analysts prefer GUTS or OCGN?

Summary

How does Fractyl Health compare to Rezolute?

Which has stronger earnings & valuation, GUTS or RZLT?

Which has more volatility & risk, GUTS or RZLT?

Do analysts prefer GUTS or RZLT?

Is GUTS or RZLT more profitable?

Do institutionals and insiders have more ownership in GUTS or RZLT?

Does the media favor GUTS or RZLT?

Summary

How does Fractyl Health compare to Eupraxia Pharmaceuticals?

Which has more volatility & risk, GUTS or EPRX?

Does the media refer more to GUTS or EPRX?

Do analysts rate GUTS or EPRX?

Which has stronger valuation and earnings, GUTS or EPRX?

Is GUTS or EPRX more profitable?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

GUTS vs. The Competition

Fractyl Health Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools